Concord Healthcare Group Co., Ltd. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 董事會提名委員會工作規則 第一章 總則 第一條 為規範美中嘉和醫學技術發展集團股份有限公司（以下簡稱「本公司」） 董事和高級管理人員的選聘工作，根據《中華人民共和國公司法》（以下簡稱「《公 司法》」）、《上市公司治理準則》、《香港聯合交易所有限公司證券上市規則》（以下 簡稱「《上市規則》」）、《美中嘉和醫學技術發展集團股份有限公司章程》（以下簡稱 「《章程》」）及其它有關規定，特設立董事會提名委員會，並制定本工作規則。 第二條 董事會提名委員會是董事會根據《章程》設立的專門工作機構，主要負責 擬定本公司董事、高級管理人員的選任程序和標準，對擬任人選的任職資格和條 件進行初步審核，並向董事會提出建議。 第三條 董事會提名委員會對董事會負責，並向董事會報告工作。 第二章 人員組成 第四條 董事會提名委員會由不少於三名董事組成，過半數成員應為本公司的獨 立非執行董事。 第五條 董事會提名委員會委員經董事會過半數選舉產生。 第六條 董事會提名委 ...

公告 取消監事會並建議修訂《公司章程》、 《股東會議事規則》及《董事會議事規則》 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 經美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事會」）審議 通過，根據《中華人民共和國公司法》《上市公司章程指引》等法律法規、規範性 文件的最新規定，結合公司實際情況，董事會同意取消監事會的設置，監事會的 職權由董事會審核委員會行使，《監事會議事規則》相應廢止。同時本公司依據 《上市公司章程指引》等相關規定，對《公司章程》、《股東會議事規則》及《董事會 議事規則》相關條款進行修訂。相關建議修訂詳情請參見本公告附錄I、附錄II及 附錄III。 董事會認為，《公司章程》、《股東會議事規則》及《董事會議事規則》之建議修訂 符合本公司及本公 ...

Core Points - The company, Meizhong Jiahe (02453), announced that its controlling shareholder, Beijing Taihe Cheng, has released the pledge of 35.6 million H-shares [1] - As of the announcement date, Beijing Taihe Cheng holds approximately 35.6 million H-shares, representing about 4.54% of the company's total issued shares [1] Summary by Sections - **Pledge Release**: On October 27, 2025, the pledge of 35.6 million H-shares by Beijing Taihe Cheng was fully released [1] - **Shareholding Details**: Beijing Taihe Cheng's shareholding remains at 35.6 million H-shares, which constitutes approximately 4.54% of the total issued shares of the company [1]

Core Points - The company, Meizhong Jiahe (02453), announced that its controlling shareholder, Beijing Taihe Cheng, agreed to pledge 35.6 million H-shares to Shanghai Pudong Development Bank as the beneficiary [1] - On October 27, 2025, the company received notification from Beijing Taihe Cheng that the pledge was fully released on the same day [1] - As of the date of the announcement, Beijing Taihe Cheng holds approximately 35.6023 million H-shares, representing about 4.54% of the company's total issued shares [1]

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 公告 控股股東股份質押解除 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 茲提述美中嘉和醫學技術發展集團股份有限公司（「本公司」）日期為2024年5月20 日及2025年8月26日之公告（「該等公告」）。除另有界定外，本公告所用詞彙與該 等公告所界定者具有相同涵義。 誠如該等公告所披露，浦發銀行同意向廣州醫院授出高達人民幣13億元的非循環 信貸。根據授信額度協議的條款及條件，並為進一步擔保本公司於授信額度協議 項下的責任及提供額外擔保，於2025年8月26日，本公司控股股東（定義見香港聯 合交易所有限公司證券上市規則）北京泰和誠同意以浦發銀行為受益人質押本公 司35.6百萬股H股（「該質押」）。 本公司於2025年10月27日收到北京泰和誠的通知，該質押已於2025年10月2 ...

Core Viewpoint - Meizhong Jiahe has achieved a significant milestone by obtaining the Medical Device Registration Certificate for its AI-developed medical image processing software, marking a breakthrough in the field of medical imaging and digital healthcare [2] Group 1: Product Development and Certification - The software, named HXK-MAICOPPET-1-001, has been officially registered by the Beijing Drug Administration, indicating compliance with regulatory standards [2] - This software addresses clinical challenges associated with traditional PET-CT imaging, which is crucial for early cancer diagnosis and treatment evaluation [2][3] - The platform adheres to international DICOM3.0 standards and employs advanced image processing algorithms for multi-modal image fusion, lesion segmentation, and 3D reconstruction [2] Group 2: Clinical Impact and Efficiency - The software significantly reduces the workload for physicians by automating image processing and providing quantitative parameters for lesion assessment, thus enhancing diagnostic efficiency and consistency [3] - Although the system is currently an auxiliary tool and does not provide independent diagnostic capabilities, it optimizes workflow and alleviates the scarcity of quality medical resources [3] Group 3: Strategic Positioning and Future Growth - Meizhong Jiahe's strategy focuses on "technology leading tumor diagnosis and treatment," expanding its capabilities from treatment to diagnosis, thereby creating a comprehensive tumor management ecosystem [3] - The company aims to extend high-level imaging analysis capabilities to lower-tier cities and remote areas, promoting the effective sharing of quality medical resources [3][4] - With the integration of its software platform, Meizhong Jiahe is positioned to enhance its precision medical system, connecting proton therapy, imaging diagnosis, and intelligent decision-making [4]

Summary of Key Points Core Viewpoint - As of October 14, a total of 75 stocks reached their 52-week highs, with notable performances from Lihua Securities Holdings (08350), Deutsche Bank Tianxia (02418), and Chuangsheng Holdings (02680) [1]. 52-Week Highs - Lihua Securities Holdings (08350) achieved a closing price of 0.325, with a peak of 0.390, marking a high rate of 34.48% - Deutsche Bank Tianxia (02418) closed at 8.120, reaching a maximum of 8.990, with a high rate of 24.86% - Chuangsheng Holdings (02680) closed at 12.100, peaking at 12.350, with a high rate of 23.50% - Other notable stocks include Century United Holdings (01959) with a high rate of 20.97% and Silicon Xin Group (08349) with 14.38% [1]. 52-Week Lows - Hengda Group Holdings (03616) recorded a closing price of 0.345, with a low of 0.300, reflecting a decline rate of -11.76% - China Technology Industry Group (08111) reached a low of 0.085, with a decline rate of -8.89% - Other significant declines include Golden Leaf International Group (08549) at -8.06% and Changfeng Pharmaceutical (02652) at -4.90% [3].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美中嘉和醫學技術發展集團股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02453 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 313,874,624 | RMB | | 1 | RMB | | 313,874,624 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 313,874,624 | RMB | | 1 | RMB | | 313,874,624 | | 2. 股份 ...

Core Insights - The company, Meizhong Jiahe Medical Technology Development Group, has received academic recognition with its director, Professor Qian Zhaonan, being listed in the "Top 2% of Scientists Worldwide (2025)" by Stanford University and Elsevier, highlighting its research and clinical capabilities in the field of head and neck tumors, particularly nasopharyngeal carcinoma [1][2] Group 1: Academic Recognition - Professor Qian Zhaonan has been included in the prestigious list for six consecutive years, indicating his sustained academic influence and contributions to the field of oncology [1][2] - The list is recognized globally for its rigorous selection criteria, which focus on genuine academic contributions, thus enhancing the credibility of the recognition [1] Group 2: Clinical Impact - The recognition signifies that the company's research outcomes are being effectively translated into clinical practices, establishing a competitive edge in the market [2] - The hospital has developed a unique treatment system focusing on nasopharyngeal carcinoma while also covering multiple diseases, showcasing its innovative approaches in proton therapy [2] Group 3: Strategic Direction - The company emphasizes a strategy of "research-driven + international collaboration," which has been pivotal in attracting top talent and enhancing its research capabilities [3] - Future plans include increasing investment in research, particularly in proton therapy, immunotherapy, and artificial intelligence applications in treating nasopharyngeal carcinoma and other prevalent tumors [3]

Investment Rating - The report rates the automotive industry as "Positive" [4] Core Insights - The adjustment of the vehicle replacement policy will slightly weaken demand, but the reduction in vehicle purchase tax will promote early purchases, leading to a competitive demand scenario in Q4. As of September 10, 2025, the number of applications for vehicle replacement reached 8.3 million, indicating a significant policy-driven effect. Despite the adjustments in the replacement policy, the pressure from the tax reduction is expected to encourage consumers to purchase new energy vehicles earlier. The report forecasts that China's new energy vehicle sales will reach 16.25 million units in 2025, representing a year-on-year growth of approximately 26% [2][18]. Monthly Focus - The adjustment of the vehicle replacement policy has increased application difficulty. Since June, applications for vehicle replacement have been suspended due to the exhaustion of funds, but recent funding has led to adjustments in the policy across various regions. The adjustments mainly include changes in application methods and subsidy standards, with some regions reducing the subsidy amount per vehicle [14][15]. - There is a significant funding gap for Q4, as the distribution of funds does not account for seasonal consumption patterns. The central government will allocate 69 billion yuan for Q4, which is the same as Q3, but the demand for vehicle consumption is typically stronger in the second half of the year, leading to an amplified funding gap for Q4 [16][17]. Key Data Tracking - In August, the sales of new energy vehicles in China reached 1.4 million units, a year-on-year increase of 27%. The penetration rate for new energy vehicles was 49%, remaining stable compared to the previous month. However, the sales of plug-in hybrid vehicles (PHEVs) experienced a decline for two consecutive months, primarily due to pressure on sales from major manufacturers [20][28]. - The report highlights that commercial vehicles and exports continue to maintain high growth rates, with new energy commercial vehicle sales in August reaching 70,000 units, a year-on-year increase of 52% [34][35]. - The report also notes that the export of new energy vehicles has been robust, with August exports reaching 224,000 units, a year-on-year increase of 104% [46][48]. Industry and Company Changes - The report indicates progress in the overseas production capacity of automotive companies, with several manufacturers establishing production bases in regions like Brazil and Austria. Additionally, companies like Chery and HeSai have listed on the Hong Kong stock exchange, while Dongfeng Group plans to privatize and spin off its Lantu brand to maintain its listing status [3][45].